In recent years, several antibody–drug conjugates (ADC) targeting Trop-2 have been developed, demonstrating significant therapeutic efficacy in triple-negative breast cancer (TNBC) and NSCLC [17–19]. Here, TACSTD2 is linked to non-small cell lung carcinoma.